RxDoctor Payments Data

Lacy Estes, APRN

Family · Belmont, MSNPI 1275148967

Payments from drug & device makers

$999in general payments, 2019–2025

Across 65 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$460
  • Amgen$188
  • Novo Nordisk$140
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$49
  • AstraZeneca$49
  • Boehringer Ingelheim$36
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$999100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$999 in reported general payments places this provider in the 65th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$2,206
Medicare patients
24
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$46,852
MounjaroTirzepatide20$20,663
FarxigaDapagliflozin Propanediol19$15,650
EliquisApixaban23$12,247
Soliqua 100-33Insulin Glargine/Lixisenatide12$11,130
JanuviaSitagliptin Phosphate20$10,833
MyrbetriqMirabegron11$6,784
Dexlansoprazole DrDexlansoprazole11$1,985
Albuterol Sulfate HfaAlbuterol Sulfate48$1,537
Gabapentin102$1,327
Duloxetine Hcl32$1,244
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen98$1,172
Pantoprazole Sodium83$1,145
Buspirone Hcl54$1,028
Diclofenac Sodium19$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$140$46,85239 claims
AstraZenecaFarxiga$49$15,65019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,007 family providers in Mississippi.

Other family in Belmont

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →